Federal appeals court bars generics for Otezla until 2028
A US appeals court has given Amgen more time to profit off its psoriasis and psoriatic arthritis blockbuster Otezla — with five more years until generics makers Sandoz and Zydus can enter Amgen’s stomping grounds.
The US Court of Appeals for the Federal Circuit handed down the ruling Wednesday, affirming a 2021 ruling in Amgen’s favor.
According to the ruling, the appeals court looked at multiple claims from Sandoz that the lower, district court had erred on multiple claims of patent infringement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
